Psyence Biomedical Ltd. (PBM) Liabilities and Shareholders Equity (2023 - 2026)
Psyence Biomedical (PBM) posted quarterly Liabilities and Shareholders Equity of $17.6 million for Q1 2026, up 140.11% year-over-year from $7.3 million in Q1 2025, and up 37.14% quarter-over-quarter from $12.8 million in Q3 2025.
Psyence Biomedical Ltd. (PBM) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Psyence Biomedical's Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $17.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 140.11% year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $39.9 million (up 273.27% YoY), while the FY2026 annual figure was $17.6 million, up 140.11% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $17.6 million, up from $12.8 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $17.6 million in Q1 2026, with the low at $12.68 in Q3 2023.
- The 4-year median for Liabilities and Shareholders Equity is $2.3 million (2024), against an average of $6.1 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 17770964.17% in 2024, while the deepest fall reached 38.14% in 2024.
- Psyence Biomedical's Liabilities and Shareholders Equity stood at $12.68 in 2023, then soared by 17770964.17% to $2.3 million in 2024, then surged by 468.46% to $12.8 million in 2025, then surged by 37.14% to $17.6 million in 2026.
- Business Quant data shows PBM's Liabilities and Shareholders Equity at $17.6 million in Q1 2026, $12.8 million in Q3 2025, and $7.3 million in Q1 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.57 Mn |
| Sep 30, 2025 | 12.81 Mn |
| Mar 31, 2025 | 7.32 Mn |
| Sep 30, 2024 | 2.25 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Sep 30, 2023 | 12.68 |
| Mar 31, 2023 | 1.83 Mn |